Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus

Clinical and Experimental Immunology

Volumn 129, Issue 2, 2002, Pages 359-369

  Mihara, S ^a,b   Suzuki, N ^a   Takeba, Y ^a   Soejima, K ^c   Yamamoto, S ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Apoptosis; Epitope; Human; Molecular mimicry; Tolerance

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CROSS REACTING ANTIBODY; EPITOPE; FAS LIGAND; PROTEIN; SYNTHETIC PEPTIDE;

ADOLESCENT; ADULT; AMINO ACID COMPOSITION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DELETION MUTANT; EPITOPE MAPPING; FEMALE; HUMAN; INHIBITION KINETICS; LYMPHOCYTE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MOLECULAR MODEL; POINT MUTATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THREE DIMENSIONAL IMAGING;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD95; AUTOANTIBODIES; AUTOANTIGENS; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA, COMPLEMENTARY; EPITOPE MAPPING; FAS LIGAND PROTEIN; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROMOLECULAR SUBSTANCES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POINT MUTATION; RABBITS;

EID: 0036380725     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01812.x     Document Type: Article

References (55)

1. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338:1359-68.
2. Madaio MP. B cells and autoantibodies in the pathogenesis of lupus nephritis. Immunol Res 1998; 17:123-32.
3. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303-6.
4. Radic MZ, Weigert M. Origins of anti-DNA antibodies and their implications for B-cell tolerance. Ann NY Acad Sci 1995; 764:384-96.
5. Canbral AR, Alarcon-Segovia D. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1998; 10:409-16.
6. Elkon K. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:384-8.
7. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996; 39:894-903.
8. Tsokos GC. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1995; 7:376-83.
9. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythe-matosus. Annu Rev Immunol 1998; 16:261-92.
10. Tsao BP, Cantor RM, Kalunian KC, Wallace DJ, Hahn BH, Rotter JI. The genetic basis of systemic lupus erythematosus. Proc Assoc Am Physicians 1998; 110:113-7.
11. Elkon KB. Apoptosis in SLE - too little or too much? Clin Exp Rheumatol 1994; 12:553-9.
12. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37:1415-20.
13. Rose LM, Latchman DS, Isenberg DA. Bcl-2 and Fas, molecules which influence apoptosis. A possible role in systemic lupus erythematosus? Autoimmunity 1994; 17:271-8.
14. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341:1251-4.
15. Tax WJ, Kramers C, van Bruggen MC, Berden JH. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 1995; 48:666-73.
16. Elkon K. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:384-8.
17. Takeno M, Nagafuchi H, Kaneko S et al. Autoreactive T cell clones from patients with SLE support polyclonal autoantibody production. J Immunol 1997; 158:3529-38.
18. Nagata S, Golstein P. The Fas death factor. Science 1995; 267:1449-56.
19. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-78.
20. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16:39-43.
21. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969-76.
22. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins JA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
23. Suda T, Nagata S. Why do defects in the Fas-Fas ligand system cause autoimmunity? J Allergy Clin Immunol 1997; 100:S97-101.
24. Alderson MR, Tough TW, Davis-Smith T et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181:71-7.
25. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993; 14:338-9.
26. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95). Nature 1995; 373:438-41.
27. Brunner T, Mogil RJ, LaFace D et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373:441-4.
28. Ju S-T, Panka DJ, Cui H et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373:444-8.
29. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1:365-71.
30. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9:243-69.
31. Rathmell JC, Cooke MP, Ho WY et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 1995; 376:181-4.
32. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-62.
33. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186:2045-50.
34. Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999; 8:508-13.
35. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40:1126-9.
36. Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100:2622-33.
37. McNally J, Yoo DH, Drappa J et al. Fas ligand expression and function in systemic lupus erythematosus. J Immunol 1997; 159:4628-36.
38. Kovacs B, Liossis SN, Dennis GJ, Tsokos GC. Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 1997; 25:213-21.
39. Lorenz HM, Grunke M, Hieronymus T et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997; 40:306-17.
40. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98:1107-13.
41. Vaishnaw AK, Toubi E, Ohsako S et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum 1999; 42:1833-42.
42. Mysler E, Bini P, Drappa J et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994; 93:1029-34.
43. Sakata K, Sakata A, Vela-Roch N et al. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes. Eur J Immunol 1998; 28:2648-60.
44. Suzuki N, Ichino M, Mihara S, Kaneko S, Sakane T. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41:344-53.
45. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
46. Brenner CA, Tam AW, Nelson PA et al. Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques 1989; 7:1096-103.
47. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139:271-9.
48. Kaneko S, Suzuki N, Koizumi H, Yamamoto S, Sakane T. Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. Clin Exp Immunol 1997; 109:185-93.
49. Harlow ED, Lane D. Antibodies, a laboratory manual. New York: Cold Spring Harbor Laboratory, 1988.
50. Kayagaki N, Yamaguchi N, Nagao F et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 1997; 94:3914-9.
51. Kanda Y, Tanaka Y, Shirakawa K et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 1998; 22:751-4.
52. Schneider P, Bodmer JL, Holler N et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem 1997; 272:18827-33.
53. Banner DW, D'Arcy A, Janes W et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73:431-45.
54. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:3019-26.
55. Shoenfeld Y, Alarcon-Segovia D, Buskila D et al. Frontiers of SLE: review of the 5th International Congress of Systemic Lupus Erythematosus, Cancun, Mexico, April 20-25, 1998. Semin Arthritis Rheum 1999; 29:112-30.